Effect of venlafaxine and nicotine on the level of neurotransmitters and their metabolites in rat brains

• Autorzy: Czubak A. , Nowakowska E. , Golembiowska K. , Kus K. , Burda K. , Metelska J.
• Języki publikacji: EN

Abstrakty

EN

Nicotine (NIC) and venlafaxine (VEN) have been proved to exert antidepressant activity in both human and animals. The effect of antidepressant doses of NIC and VEN (our previous results) on noradrenergic (NA), dopaminergic (DA), serotoninergic (5-HT) neurotransmitters and their metabolites: DOPAC, HVA and 5-HIAA in rats’ hippocampus in freely moving rats were determined by microdialysis technique and HPLC method. Both drugs release 5-HT and NA, but VEN to a greater degree. DA level was affected only by VEN, however NIC extended the response of the DA system on VEN’s effect. Combined administration of drugs caused the greatest changes in the 5-HT system. Both drugs contributed to reduction in neurotransmitter biotransformation.

Słowa kluczowe

EN

nicotine; venlafaxine; antidepressant; neurotransmitter; rat; brain; microdialysis; noradrenaline; dopamine; hippocampus; depressive disorder; man; animal

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 3
• Opis fizyczny: p.339-346,fig.,ref.

Twórcy

autor

Czubak A.

• Karol Marcinkowski University of Medical Sciences, 75 Dabrowskiego Street, 60-529 Poznan, Poland

autor

Nowakowska E.

autor

Golembiowska K.

autor

Kus K.

autor

Burda K.

autor

Metelska J.

Bibliografia

• Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-226.
• Heninger G, Delgado P, Charney D. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from the monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2-11.
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psych 1999; 156: 286-293.
• Miller H, Ekstrom D, Mason G, Lydiard R, Lydiard RB, Gulden RN. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharma cology 2001; 24: 617-623.
• Nowakowska E, Kus K, Bobkiewicz-Kozlowska T, Hertmanowska H. Role of neuropeptides in antidepressant and memory improving effects of venlafaxine. Pol J Pharmacol 2002; 54: 605-613.
• Nowakowska E, Kus K, Chodera A. Comparison of behavioural effects of venlafaxine and imipramine in rats. Arzneimittelforschung 2003; 53: 237-242.
• Nowakowska E, Kus K, Florek E, Czubak A., Jodynis-Liebert, J, Hertmanowska H. The influence of tobacco smoke and nicotine on antidepressant and memory improving effects of venlafaxine. Hum Exp Toxicol 2006; 25: 199-209.
• Czubak A, Nowakowska E, Kus K, Matschay A, Kokot Z. The effects of nicotine and mecamylamine on spatial memory in rats. Eur Neuropsychopharmacol 2007; 17: 253-254.
• Tizabi Y, Rezvani AH, Russell LT, et al. Depressive characteristics of FSL rats: involvement of central nicotinic receptors. Pharmacol Biochem Behav 2000; 66: 73-77.
• Brioni J, Decker M, Sullivan J, Arneric SP. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv Pharmacol 1997; 37: 153-214.
• Levin E, Simon B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998; 138: 217-230.
• Newhouse P, Potter A, Levin E. Nicotinic system involvement in Alzheimer’s and Parkinson’s diseases: implications for therapeutics. Drug Aging 1997; 11: 206-228.
• Biala G, Krukl M, Budzynska B. Effects of the cannabinoid receptor ligands on anxiety-related effects of D-amphetamine and nicotine in the mouse elevated plus maze test. J Physiol Pharmacol 2009; 60(2): 113-122.
• Kolb B, Whishaw IQ. Brain plasticity and behavior. Annu Rev Psychol 1998; 49; 43-64.
• Tokarski K, Pitra P, Duszynska B, Hess G. Imipramine countracts corticosterone-induced alterations in the effects of the activation of 5-HT7 receptors in rat hippocampus. J Physiol Pharmacol 2009; 60(2): 83-88.
• Paxinos G, Watson C. A stereotaxic atlas of the rat brain. New York, Academic Press, 1998.
• Golembiowska K, Dziubina A. Striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 2004; 47: 414-426.
• Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002; 71: 555-568.
• Manji H, Quiroz J, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003; 53: 707-742.
• Addy NA, Nakijama A, Levin ED. Nicotinic mechanisms of memory: effects of acute local DhbetaE and MLA infusions in the basolateral amygdala. Brain Res Cog Brain Res 2003; 16: 51-57.
• Decker M, Brioni I, Bannon A, Arneric SP. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 1995; 56: 545-570.
• Rezvani A, Levin E. Nicotine-alcohol interactions and attentional performance on an operant visual signal detection task in female rats. Pharmacol Biochem Behav 2003; 76: 75-83.
• Tizabi Y, Overstreet D, Rezvani A, Louis VA, Clark E, Kling MA. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 1999; 142: 193-199.
• Semba J, Mataki C, Yamada S, Nankai M, Toru M. Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 1998; 43: 389-391.
• Rossi S, Singer S, Shearman E, Sershen H, Lajtha A. The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurochem Res 2005; 30: 541-558.
• Sershen H, Balla A, Lajtha A, Vizi ES. Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus. Neuroscience 1997; 77: 121-130.
• Kiianamaa K, Tuomainen P, Makova N, et al. The effects of nicotine on locomotor activity and dopamine overflow in the alcohol-preferring AA and alkohol-avioding ANA rats. Eur J Pharmacol 2000; 407: 293-302.
• Kirch D, Gerhardt G, Shelton L, Freedman R, Wyatt RJ. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol 1987; 10: 376-383.
• Shearman E, Rossi S, Sershen H, Hashim A, Lajtha A. Locally administered low nicotine-induced neurotransmitter changes in areas of cognitive function. Neurochem Res 2005; 30: 1055-1066.
• Kubo T, Amano H, Kurahashi K, Misu Y. Nicotine-induced regional changes in brain noradrenaline and dopamine turnover in rats. J Pharmacobiodyn 1989; 12: 107-112.
• Mitchell S, Smith K, Joseph M, Grey JA. Increases in tyrosine hydroxylase messenger RNA in the locus coeruleus after a single dose of nicotine are followed by time-dependent increases in enzyme activity and noradrenaline release. Neuroscience 1993; 56: 989-997.
• Wrzosek A, Obara I, Wordliczek J, Przewlocka B. Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain: an isobolographic analysis. J Physiol Pharmacol 2009; 60(4): 71-78.